Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vigil Neuroscience, Inc.
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
August 01, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
July 30, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
July 24, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
July 18, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
July 18, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
June 27, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present in Upcoming June Investor Conferences
May 30, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 08, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 26, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
March 20, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
March 13, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
March 06, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
February 29, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
February 07, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
January 03, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
November 22, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
November 16, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
October 17, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
September 26, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
September 11, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
September 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
September 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
August 07, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.